Cancer-related Venous Thromboembolic Disease - Cohort Study

Summary

Venous thromboembolic disease (VTE) is a common (1/1000), potentially serious disease (10% mortality when the clinical presentation is that of pulmonary embolism (PE)). In cancer patients, the risk of developing VTE is high and constitutes a negative prognostic factor for cancer; the risk of bleeding is also increased. The study of VTE in the context of cancer is a major challenge, given the frequency of the association, the heterogeneity of the situations, the risk factors involved and the therapeutic issues in both curative and primary prevention; in this field, many uncertainties remain, justifying a study focused on the association of VTE and cancer.

Eligibility

Inclusion Criteria:

* Patients aged 18 years and more.
* Patients with active cancer or requiring cancer treatment at the time of their VTE episode
* Patients with documented VTE less than 2 years old
* Patients affiliated to the social security system
* Patient who has signed a written informed consent

Exclusion Criteria:

* Patient under 18
* Refusal to participate
* Incapacity to consent to the study
* Patient under guardianship
* Incapacity to communicate (comprehension disorder)
* Life expectancy of less than 6 months

Conditions3

Browse More Trials